The pharmaceutical company Darnytsia has entered a new market and registered its first medicinal product in New Zealand. In this region, the Ukrainian manufacturer also supplies medicines to Australia and Singapore.
According to Darnytsia's press service, the product in question is Furosemide. It is used for the comprehensive treatment of heart and kidney failure, liver diseases, and arterial hypertension.
"New Zealand is a country with very strict regulations and high standards for the quality of medicinal products. The fact that Darnytsia's medicine has passed the rigorous registration process in this country once again proves that Ukrainian medicines are on par with global standards in terms of safety, quality, and efficacy," reads the manufacturer's post on Facebook.
The company is actively expanding its global presence. Currently, Ukrainian-produced medicines are exported to Europe and countries in the Asia-Pacific region. Last year, Darnytsia shipped a batch of medicines to Australia and also registered medicines for treating heart and kidney failure in Singapore and Poland.
"Despite the challenges of the full-scale war, we continue to expand our export horizons. Today, Darnytsia medicines are exported to Europe and countries in the Asia-Pacific region. The list of countries will continue to grow as our medicines are safe, effective, efficient, and fully comply with the requirements of the most stringent global regulations," says Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.
Darnytsia is a Ukrainian pharmaceutical company founded in 1930. It produces over 180 products in 15 different forms (tablets, solutions, etc.), focusing on cardiology, neurology, and pain management.
